REGENERON PHARMACEUTICALS (REGN)
US75886F1075 - Common Stock
REGENERON PHARMACEUTICALS
NASDAQ:REGN (12/20/2024, 8:00:01 PM)
After market: 706.33 +4.48 (+0.64%)701.85
-6.4 (-0.9%)
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 13,450 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Company Info
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK 10591
P: 17813705000
CEO: Leonard S. Schleifer
Employees: 13926
Website: https://www.regeneron.com/
REGN News
3 days ago - Regeneron Pharmaceuticals, Inc.Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results3 days ago - Regeneron Pharmaceuticals, Inc.Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept ResultsInvestigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing...
4 days ago - Regeneron Pharmaceuticals, Inc.Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference4 days ago - Regeneron Pharmaceuticals, Inc.Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceTARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P....
4 days ago - ChartmillStay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.Which S&P500 stocks are moving on Tuesday?
5 days ago - Regeneron Pharmaceuticals, Inc.EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein OcclusionREGN Twits
Here you can normally see the latest stock twits on REGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
